Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ...

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

Modifying the physical characteristics of microscopic biomaterials to interact seamlessly with the body's tissues could ...

Proteins are the workhorses that keep our cells running, and there are many thousands of types of proteins in our cells, each performing a specialized function. Researchers have long known that the ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for ...